Montelukast Stada (Montelukast)

Montelukast selectively blocks the cysteinyl leukotriene receptor type 1 (CysLT1) on airway smooth‑muscle cells and inflammatory cells. By preventing leukotrienes such as LTC4, LTD4 and LTE4 from binding, it inhibits bronchoconstriction, mucus secretion, vascular leakage and eosinophilic inflammation that contribute to asthma and allergic symptoms.

The dosage of Montelukast Stada is determined by the prescribing clinician based on the patient’s age, weight, indication and overall treatment plan. The prescriber selects the appropriate strength and administration schedule in accordance with local labeling and clinical guidelines; patients should follow the exact instructions provided on the prescription label.

Safety data for Montelukast in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any potential risk to the fetus. Regarding lactation, small amounts may be excreted in breast milk; a healthcare professional should evaluate the risk‑benefit before continuing therapy while nursing.

To place an order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide institutional or trade credentials. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming eligibility, then replies with pricing, availability, shipping terms (including any required temperature control) and assistance with import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting β‑agonists. It is particularly useful for patients with aspirin‑exacerbated respiratory disease or those who prefer a tablet form. While it provides modest improvement in lung function, it is generally less potent than inhaled steroids for severe asthma, and is often used as add‑on therapy.

Montelukast Stada tablets should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the product in its original container, protect it from moisture, heat and direct sunlight. Do not refrigerate or freeze the tablets, and ensure they are kept out of reach of children.

Montelukast Stada is taken orally, usually once daily in the evening with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water; it should not be chewed, crushed or split unless the specific formulation permits. Consistent timing helps maintain steady drug levels.

Serious adverse events, although rare, include severe allergic reactions such as angioedema or anaphylaxis, neuropsychiatric effects like depression or suicidal thoughts, and rare skin disorders such as Stevens‑Johnson syndrome. Clinicians should monitor patients for any new or worsening mood changes, hypersensitivity signs, or severe skin eruptions, and discontinue the drug promptly if such events occur.

Montelukast Stada is contraindicated in individuals with known hypersensitivity to montelukast sodium or any of the tablet excipients. It should also be avoided in patients who have experienced severe allergic reactions to leukotriene‑modifying agents. Caution is advised in patients with active liver disease, uncontrolled psychiatric conditions, or those taking interacting enzyme‑inducing medications.